AlphaQuest LLC Buys 34,011 Shares of Halozyme Therapeutics, Inc. $HALO

AlphaQuest LLC increased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 640.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 39,319 shares of the biopharmaceutical company’s stock after purchasing an additional 34,011 shares during the period. AlphaQuest LLC’s holdings in Halozyme Therapeutics were worth $2,884,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of HALO. CWM LLC grew its holdings in shares of Halozyme Therapeutics by 2,136.0% in the 3rd quarter. CWM LLC now owns 23,881 shares of the biopharmaceutical company’s stock valued at $1,751,000 after acquiring an additional 22,813 shares in the last quarter. Arbor Investment Advisors LLC bought a new stake in Halozyme Therapeutics during the third quarter worth about $1,316,000. Monument Capital Management acquired a new position in Halozyme Therapeutics during the third quarter valued at approximately $2,015,000. Pacer Advisors Inc. grew its stake in Halozyme Therapeutics by 2,054.7% in the third quarter. Pacer Advisors Inc. now owns 478,874 shares of the biopharmaceutical company’s stock valued at $35,121,000 after purchasing an additional 456,649 shares in the last quarter. Finally, Cardinal Capital Management acquired a new position in shares of Halozyme Therapeutics during the 3rd quarter worth approximately $1,303,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

NASDAQ:HALO opened at $71.71 on Friday. The company has a market cap of $8.43 billion, a P/E ratio of 15.10, a P/E/G ratio of 0.32 and a beta of 0.94. The firm’s fifty day moving average price is $68.93 and its two-hundred day moving average price is $68.36. Halozyme Therapeutics, Inc. has a one year low of $47.50 and a one year high of $79.50. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.59 and a quick ratio of 1.37.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 EPS for the quarter, topping the consensus estimate of $1.63 by $0.09. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The business had revenue of $354.26 million during the quarter, compared to the consensus estimate of $339.18 million. During the same quarter in the previous year, the firm posted $1.27 EPS. Halozyme Therapeutics’s revenue was up 22.1% compared to the same quarter last year. Equities analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Analyst Upgrades and Downgrades

HALO has been the subject of several recent analyst reports. JPMorgan Chase & Co. increased their price objective on Halozyme Therapeutics from $63.00 to $65.00 and gave the company a “neutral” rating in a report on Monday, October 27th. Zacks Research cut shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Morgan Stanley lowered their price objective on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating on the stock in a research note on Monday, October 20th. Citizens Jmp upped their target price on shares of Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a report on Tuesday, November 4th. Finally, HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday. Seven investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Halozyme Therapeutics presently has an average rating of “Hold” and a consensus price target of $78.80.

Insider Activity at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $69.13, for a total transaction of $1,382,600.00. Following the transaction, the chief executive officer owned 733,719 shares in the company, valued at approximately $50,721,994.47. This trade represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bernadette Connaughton sold 2,000 shares of the business’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $68.48, for a total value of $136,960.00. Following the completion of the sale, the director owned 42,952 shares of the company’s stock, valued at $2,941,352.96. This trade represents a 4.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 41,398 shares of company stock worth $2,861,352 in the last ninety days. 2.40% of the stock is owned by company insiders.

Halozyme Therapeutics News Summary

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Preliminary 2025 results beat expectations and management raised 2026 outlook — the upbeat update helped push shares higher on Jan. 29 as revenue and profitability momentum improved, supporting the company’s longer‑term earnings trajectory. HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance
• Positive Sentiment: Halozyme announced an acquisition of Surf Bio for up to $400M — this expands its pipeline/technology footprint tied to the ENHANZE platform and is a strategic revenue/pipeline bolt‑on that can accelerate growth if integrations and deal economics play out as expected. Halozyme Acquires Surf Bio for up to $400M
• Positive Sentiment: H.C. Wainwright reiterated a Buy rating and kept a $90 price target — a prominent sell‑side endorsement that supports upside vs. current levels and highlights confidence in the ENHANZE platform’s commercial contribution. H.C. Wainwright Sees Strength in Halozyme Therapeutics’ ENHANZE Platform, Reiterates Buy Rating
• Positive Sentiment: Market commentary highlights HALO as a momentum name based on style scores and recent earnings/guidance — this can attract momentum and quant flows. Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
• Neutral Sentiment: A valuation/markets piece examines whether HALO still offers value after multi‑year gains — useful context for longer‑term investors weighing current price vs. growth expectations. Is Halozyme Therapeutics (HALO) Offering Value After Strong Multi‑Year Share Price Gains
• Negative Sentiment: Zacks Research issued minor downward tweaks to several near‑term quarterly EPS estimates and kept a “Hold” stance — small cuts to Q2 2026 and Q3 2027 forecasts (and only tiny upward tweaks to other quarters) may have trimmed near‑term sentiment and contributed to selling/profit taking. (Zacks updates consolidated from analyst notes.)

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.